# Tumour flare on bispecific antibodies and lenalidomide in lymphoma: recognition and management

Source: https://onco.cc/protocols/tumour-flare-on-bispecific-antibodies-and-immunomodulatory-drugs/  
OnCo record `tumour-flare-on-bispecific-antibodies-and-immunomodulatory-drugs` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some lymphoma medicines draw immune cells into the lymphoma, so lumps can swell and hurt for days or sometimes weeks. This is tumour flare, and it can look like the cancer growing when it is not. Painkillers and sometimes steroids are used. A lump near the windpipe or another vital organ can press on it, so tell your team straight away about swollen or sore lumps, chest pain or trouble breathing.

## Summary

Tumour flare is a painful swelling of lymphoma sites, sometimes with new pleural effusions, low-grade fever or rash, in the first days to weeks of a T-cell-engaging bispecific antibody or of lenalidomide. The EU labels of all three bispecific antibodies say it is likely due to T cells moving into the tumour. It matters for two reasons: swelling next to an airway or vital organ can cause compression, and it can be mistaken for progression.

Rates and timing from the labels: glofitamab 12% (grade 3 in 2.8%), median onset 2 days after the first dose (range 1 to 16), median duration 3.5 days (range 1 to 35), almost all in cycle 1; mosunetuzumab 4% (US label) or 3.1% (EU label, median onset 13 days, median duration 36 days); epcoritamab 1.6% as monotherapy with a median onset of 19.5 days (EU label). On lenalidomide it was reported in 10% of patients in the mantle cell lymphoma trial (all grade 1 or 2, all in cycle 1), in 10.8% on lenalidomide with rituximab in the AUGMENT trial in follicular or marginal zone lymphoma (one grade 3), and in 4.1% in the MAGNIFY trial; one case in a separate mantle cell trial was fatal (US label). The US label says flare, including fatal reactions, occurred in investigational use for chronic lymphocytic leukaemia and lymphoma, and that lenalidomide is not indicated and not recommended for that leukaemia outside controlled trials.

Management is label-based. The US glofitamab and mosunetuzumab labels ask for close monitoring of people with bulky disease near an airway or vital organ during initial treatment, and all three EU labels ask for monitoring at critical anatomical sites; the US epcoritamab label gives no flare advice. The US glofitamab label withholds the drug for grade 2 to 4 flare and names an antihistamine and corticosteroids; the EU glofitamab label says corticosteroids and analgesics should be considered and has no hold rule for flare; the EU mosunetuzumab label withholds for grade 3 or 4 flare; the epcoritamab trial allowed treatment to continue through suspected flare. Lenalidomide may continue through grade 1 or 2 flare at the doctor's discretion, with NSAIDs, corticosteroids or opioid analgesics, and is withheld for grade 3 or 4 until it settles to grade 1 or less. A practice summary says flare can overlap with cytokine release syndrome and other toxicities, which are treated at the same time.

The LYRIC criteria, written for clinical trials, introduced an 'indeterminate response' category so that apparent progression on immune-modulating treatment is confirmed by biopsy or later imaging before it is called progression. No source read reports a trial comparing ways of managing flare. The reader's own team's protocol comes first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: tumour flare; tumor flare; tumour flare reaction; TFR; pseudoprogression in lymphoma; pseudo-progression; flare reaction on glofitamab; lenalidomide tumour flare; indeterminate response

## Connected records

- protocols: [Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids](https://onco.cc/protocols/crs-grading-and-management/), [Superior vena cava obstruction in cancer: recognition, imaging, stenting and treatment of the cause](https://onco.cc/protocols/svc-obstruction/), [T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery](https://onco.cc/protocols/bispecific-step-up-dosing/), [Tumour lysis syndrome: risk assessment, prophylaxis and treatment](https://onco.cc/protocols/tumour-lysis-syndrome-prevention-and-treatment/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Marginal zone lymphoma](https://onco.cc/cancers/marginal-zone-lymphoma/)
- drugs: [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Glofitamab](https://onco.cc/drugs/glofitamab/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/)
- terms: [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [Immunomodulatory drugs (IMiDs) and CELMoDs](https://onco.cc/terms/imid/), [Lugano classification / Ann Arbor staging](https://onco.cc/terms/lugano-classification/), [Tumour lysis syndrome (TLS)](https://onco.cc/terms/tumor-lysis-syndrome/)

---
JSON: https://onco.cc/api/v1/entities/tumour-flare-on-bispecific-antibodies-and-immunomodulatory-drugs.json